State Street Corp raised its stake in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 0.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,039,207 shares of the biotechnology company’s stock after buying an additional 22,864 shares during the period. State Street Corp owned 3.09% of ZIOPHARM Oncology worth $25,607,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of ZIOP. Mission Wealth Management LLC acquired a new position in ZIOPHARM Oncology during the first quarter valued at $108,000. Highbridge Capital Management LLC acquired a new position in ZIOPHARM Oncology during the fourth quarter valued at $164,000. Old West Investment Management LLC acquired a new position in ZIOPHARM Oncology during the first quarter valued at $205,000. UBS Asset Management Americas Inc. increased its position in ZIOPHARM Oncology by 79.6% in the first quarter. UBS Asset Management Americas Inc. now owns 37,687 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 16,700 shares in the last quarter. Finally, Private Advisor Group LLC increased its position in ZIOPHARM Oncology by 23.4% in the first quarter. Private Advisor Group LLC now owns 41,541 shares of the biotechnology company’s stock valued at $260,000 after buying an additional 7,875 shares in the last quarter. 38.17% of the stock is currently owned by hedge funds and other institutional investors.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) traded down 2.14% during midday trading on Friday, reaching $5.04. 522,572 shares of the company traded hands. The company’s 50-day moving average price is $5.83 and its 200 day moving average price is $6.32. ZIOPHARM Oncology Inc has a 12 month low of $4.84 and a 12 month high of $7.88. The firm’s market capitalization is $708.79 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. ZIOPHARM Oncology’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same quarter last year, the company posted ($1.01) earnings per share. On average, equities analysts anticipate that ZIOPHARM Oncology Inc will post ($0.56) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “State Street Corp Purchases 22,864 Shares of ZIOPHARM Oncology Inc (ZIOP)” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/18/ziopharm-oncology-inc-ziop-position-boosted-by-state-street-corp-updated.html.
Several equities analysts have recently weighed in on the stock. BidaskClub downgraded shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday. HC Wainwright initiated coverage on shares of ZIOPHARM Oncology in a research report on Thursday, June 1st. They set a “buy” rating and a $9.50 price objective for the company. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, April 26th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. ZIOPHARM Oncology has an average rating of “Hold” and an average price target of $13.17.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.
